Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 71

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 71
---
 or any other term or aspect of the Transaction to, or any consideration to be received in connection therewith by, or the impact of the Transaction on, the holders of any other class of securities,
creditors or other constituencies of Repare or any other party. In addition, Leerink Partners expressed no view or opinion as to the fairness (financial or otherwise) of the amount, nature or any other aspect of any compensation to be paid or
payable to any of the officers, directors or employees of Repare or any other party, or class of such persons in connection with the Transaction, whether relative to the Cash Consideration proposed to be paid to the holders of Common Shares pursuant
to the terms of the Arrangement or otherwise. The opinion of Leerink Partners’ was necessarily based on financial, economic, monetary, currency, market and other conditions and circumstances as in effect on, and the information made available
to Leerink Partners as of, the date of the opinion, and Leerink Partners does not have any obligation or responsibility to update, revise or reaffirm this opinion based on circumstances, developments or events

40

occurring after the date of the opinion. Leerink Partners’ opinion did not constitute a recommendation to any shareholder of Repare as to whether or how such holder should vote with respect
to the Transaction or otherwise act with respect to the Agreement or any other matter. Leerink Partners’ financial advisory services and its opinion were provided for the information and assistance of the Transaction Committee and the Repare
Board (in their capacity as directors and not in any other capacity) in connection with and for purposes of their consideration of the Transaction. The issuance of the opinion of Leerink Partners was approved by the Leerink Partners LLC Fairness
Opinion Review Committee.

Summary of Financial Analyses

The following is a summary of the material financial analyses prepared by Leerink Partners and reviewed with the Repare Board in connection
with its opinion, which was delivered orally to the Repare Board on November 14, 2025, and subsequently confirmed in Leerink Partners’ written opinion, dated November 14, 2025. For purposes of the analyses described below, Leerink
Partners was directed to rely upon the Dissolution Analysis prepared by Repare management. The summary set forth below does not purport to be a complete description of the financial analyses performed or factors considered by, and underlying the
opinion of Leerink Partners, nor does the order of the analyses described below represent the relative importance or weight given